

Appendix 1: Candidates for the Board of Directors

*Listed companies

**Georges Gemayel**

Chairman

Member since: 2012 (Chairman since 2014)**Born in:** 1960**Nationality:** American**Committees:** Nomination Committee (Chairman)**Special competences**

Dr. Gemayel's qualifications to sit on the Board of Directors include his significant management and executive experience in the global pharmaceutical industry.

Other management duties

Georges Gemayel is currently Chairman of the Board of Directors of Dynacure, Enterome SA, and OxThera AB and a member of the Board of Directors of Momenta Pharmaceuticals Inc. (publ)* and Supernus Pharmaceuticals Inc. (publ)*.

Previous positions

Georges Gemayel has previously been Chairman of the Board of Directors of Dimension Therapeutics Inc. (publ), Epitherapeutics ApS, Vascular Magnetics Inc., and Syndexa Pharmaceuticals Inc. as well as a member of the Board of Directors of NPS Pharmaceuticals Inc. (publ), Raptor Pharmaceuticals Corp. (publ), Prosensa N.V. (publ), and Adolor Corp. (publ).

Educational background

Georges Gemayel holds a Master and a PhD in Pharmacology from Paris-Sud University and a Docteur d'Exercice en Pharmacie from the St. Joseph University.

**Bo Jesper Hansen**

Deputy Chairman

Member since: 2010 (Deputy Chairman since 2017)**Born in:** 1958**Nationality:** Danish**Committees:** Remuneration Committee (Chairman)**Special competences**

Dr. Hansen's extensive experience in orphan drugs, both from the operations and supervisory point of view and his broad and current knowhow of the biotechnology environment makes him a qualified member of the Board of Directors.

Other management duties

Bo Jesper Hansen is currently Chairman of the Board of Directors of Laborie Inc. and Innoventa Medica ApS and a member of the Board of Directors of Azanta A/S and Ascelia Pharmaceuticals AB.

Previous positions

Bo Jesper Hansen has previously been Chairman of the Board of Directors and a member of the Executive Management of Swedish Orphan Biovitrum AB (publ), Chairman of the Board of Directors of Ablynx NV, Reaplix ApS, Topotarget A/S (publ) (dissolved by merger), Karolinska Development AB (publ) and a member of the Board of Directors of Newron Pharmaceuticals SpA, CMC Sweden AB, Hyperion Therapeutics Inc. (publ) (dissolved following acquisition), Gambro AB, Inspyr Inc. (publ), Zymenex Holding A/S, Zymenex A/S, ACE Bioscience A/S, Mipsalus Holding ApS, and MipSalus ApS.

Educational background

Bo Jesper Hansen holds an MD and PhD in Medicine from the University of Copenhagen.



Martin Bonde

Member since: 2010

Born in: 1963

Nationality: Danish

Committees: Nomination Committee

Special competences

Dr. Bonde's qualifications to sit on the Board of Directors include his executive experience and in-depth knowledge of the biotechnology environment in the Nordic countries.

Other management duties

Martin Bonde is currently Chief Executive Officer of Vaccibody AS and Bohrs Towers IVS and a member of the Board of Directors and the Executive Management of Biotopix ApS. Martin Bonde is furthermore a member of the Board of Directors of VisioPharm A/S.

Previous positions

Martin Bonde has previously been the Chairman of the Board of Directors of DANSK BIOTEK and a member of the Executive Management of Epitherapeutics ApS.

Educational background

Martin Bonde holds a Graduate Diploma in Business Administration from Copenhagen Business School, a Master of Science, and a PhD in Chemical Engineering from the Technical University of Denmark.



Rémi Droller

Member since: 2015

Born in: 1975

Nationality: French

Committees: Remuneration Committee

Special competences

Mr. Droller's extensive experience as a biotechnology investor and his proven track-record in negotiating several successful transactions make him a qualified member of the Board of Directors.

Other management duties

Rémi Droller is currently Managing Partner of Kurma Partners SA and Chairman of the Board of Directors in Dynacure SAS and ImCheck SAS. Member of the Board of Directors of OxThera AB, AM Pharma BV, STAT Dx S.L., and Pharvaris BV.

Previous positions

Rémi Droller has previously been Chairman of the Board of Directors of Step Pharma SAS and a member of the Board of Directors of Prosensa N.V. (publ) and Onxeo SA (publ).

Educational background

Rémi Droller holds a Master in Molecular Biology from Université Pierre et Marie Curie and a Master in Finance and Management of Innovation from Masternova.



Sten Verland

Member since: 2010

Born in: 1957

Nationality: Danish

Committees: Nomination Committee, Audit Committee

Special competences

Dr. Verland is a serial entrepreneur in biotechnology companies. He has extensive investment and managerial experience that make him a qualified member of the Board of Directors.

Other management duties

Sten Verland is Co-Founder and General Partner of Sunstone Life Science Ventures A/S, in the Executive Management of Verland Capital ApS, Verland Holding ApS, Verland Holding II ApS, Genobiotix ApS, and in companies in or associated with the Sunstone Group. Member of the Board of Directors of Anergis SA, Vaximm AG, MinervaX ApS, OxThera AB, Danish Venture Capital and Private Equity Association (DVCA), and in companies in or associated with the Sunstone Group.

Previous positions

Sten Verland has previously been Chairman of the Board of Directors of Zymenex Holding A/S, Zymenex A/S, Action Pharma A/S, Cytotrack ApS and a member of the Board of Directors of Rigontec GmbH, F2G Ltd., ACE Biosciences A/S, NsGene A/S, Nordic Vaccine A/S, Survac ApS, Glycom A/S, Scanbur A/S, Synarc A/S, Taconic Biosciences A/S, Biovision A/S, VetVerland ApS and Tera Holding A/S. Further, Sten Verland has previously been a member of the Executive Management of Synarc A/S, Taconic Biosciences A/S, Nordic Vaccine A/S as well as a Partner and a member of the Executive Management in certain companies in or associated with the Sunstone Group.

Educational background

Sten Verland holds a Master in Biology and Mathematics and a PhD in Immunology from the University of Copenhagen.



Martijn Kleijwegt

Member since: 2017

Born in: 1955

Nationality: Dutch

Committees: Audit Committee

Special competences

Mr. Kleijwegt is qualified to serve on the Board of Directors given his experience as a major European venture-capital investor, his experience in the pharmaceutical industry, and his service on the Boards of Directors of other biopharmaceutical companies.

Other management duties

Martijn Kleijwegt is currently Founder and Managing Partner at LSP Management Group BV. and a member of the Board of Directors of Kiadis Pharma N.V. (publ), OxThera AB, Eloxx Pharmaceuticals Ltd.*, and Pharvaris BV.

Previous positions

Martijn Kleijwegt has previously been a member of the Board of Directors of Prosensa N.V. (publ).

Educational background

Martijn Kleijwegt holds a Master's degree from the University of Amsterdam.



Anders Hedegaard

Member since: 2017

Born in: 1960

Nationality: Danish

Committees: Remuneration Committee

Special competences

Mr. Hedegaard is a sitting Chief Executive Officer of a publicly listed company. His extensive knowledge of the healthcare industry, both in product development and commercialization, makes him a qualified member of the Board of Directors.

Other management duties

Anders Hedegaard is currently Chief Executive Officer of Rodenstock Group.

Previous positions

Anders Hedegaard has previously been Chairman of the Board of Directors of GN Otometrics A/S, Aktieselskabet af 1. juni 2011 I, and BN Washington D.C. Holding A/S as well as a member of the Board of Directors of the Confederation of Danish Enterprise, Hearing Instrument Manufacturers Software Association A/S, HIMSA II A/S, Origio A/S and certain companies in or associated with the Bavarian Nordic Group. Further, Anders Hedegaard has previously been Chief Executive Officer of GN Store Nord A/S (publ), GN Hearing A/S, and Bavarian Nordic A/S and a member of the Executive Management of ALK-Abelló A/S and FOSS A/S as well as international marketing director at Novo Nordisk A/S.

Educational background

Anders Hedegaard holds a Master of Science in Chemical Engineering and Biochemistry from the Technical University of Denmark.



Catherine Moukheibir

Member since: 2017

Born in: 1957

Nationality: American, Lebanese, and British

Committees: Audit Committee (Chairman)

Special competences

Ms Moukheibir's experience in the pharmaceutical and banking industries and her successful track record in leading Audit Committees of publicly traded companies makes her a qualified member of the Board of Directors.

Other management duties

Catherine Moukheibir is currently Chairman of the Board of Directors of MedDay Pharmaceuticals SA and a member of the Board of Directors of Zealand Pharma A/S (publ)* and Genkyotex SA (publ)*.

Previous positions

Catherine Moukheibir has previously been a member of the Executive Management for Innate Pharma Inc (publ), Chairman of the Board of Directors of Creabilis and a member of the Board of Directors in Ablynx NV (publ), Cerenis Therapeutics SA (publ), and Octopus NV.

Educational background

Catherine Moukheibir holds a Master in Economics and an MBA degree, both from Yale University.